Shield Therapeutics Plc

Shield Therapeutics PLC is a commercial-stage pharmaceutical company that develops and markets novel oral treatments. Its primary aim is to address unmet medical needs for patients, particularly those with iron deficiency, with an expanding global commercial reach. Operating within the Healthcare sector, UK-based Shield Therapeutics PLC focuses on developing and commercialising oral therapies. Its lead product, ACCRUFeR®/Feraccru® (ferric maltol), is approved for treating iron deficiency with or without anaemia in adults across regions including the US, EU, UK, and Canada. Track the share price of STX.L by adding it to your eToro watchlist. This content was generated by artificial intelligence. We cannot guarantee the accuracy, completeness, or timeliness of the information provided.